Faron Pharmaceuticals: Blood cancer study BEXMAB in full swing
Faron has prepared for increased bexmarilimab production and accelerated its BEXMAB study, which resulted in higher R&D costs and a weaker result than we expected. Our estimate changes are marginal, as we recently updated our assessment of the progress of the drug development program. The valuation picture remains unchanged compared to our assessment in January, as there have been no major changes in the timing or financial outlook of the studies.
Faron Pharmaceuticals
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage. Our pipeline consists of two drug candidates and development programmes Clevegen (FP-1305) and Traumakine (FP-1201-lyo). Clevegen aims to tackle several cancer types by activating immunity; Traumakine organ trauma and vascular damage by stopping vascular leakage. Both programmes have advanced to first-in-human clinical trials following promising pre-clinical data. Faron is based in Turku, Finland.
Read more on company pageKey Estimate Figures2023-03-06
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 |
growth-% | |||
EBIT (adj.) | -27.4 | -15.8 | -3.1 |
EBIT-% (adj.) | -685,650.00 % | -394,522.50 % | -76,864.00 % |
EPS (adj.) | -0.48 | -0.25 | -0.05 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |